Epigenetics Diagnostic Market Worth Touch Around $21.7 Billion By 2026

The global epigenetics diagnostic market size is expected to reach USD 21.7 billion by 2026, expanding at a CAGR of 18.8% over the forecast period, according to a new study by Grand View Research, Inc. Growing prevalence of cancer and other diseases across the globe, along with epigenetic modification base, is anticipated to fuel the industry growth during the forecast period. 

Diagnostic companies are upgrading their products by implementing new techniques for attaining specific and sensitive results. Companies such as Abcam plc, Invitrogen, and Sigma Aldrich Corporation are developing a new range of Chromatin immunoprecipitation (ChIP)-validated antibodies specific for detection of histone modifications at various loci.

In addition, many biotechnology and pharmaceutical companies and academic research organizations are collaborating to promote the growth of the epigenetics diagnostic industry. Companies such as Epigenomics, OncoMethylome Sciences, and Orion Genomics have collaborated with other laboratories and diagnostic companies that have licensed their technology for development of Laboratory-developed Tests (LDTs).

Technological advancements resulting in increased accuracy, portability, and cost-effectiveness are expected to be a high-impact rendering driver in the market. For instance, Diagenode has developed automated kits for detection and purification of methylated DNA.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/epigenetics-diagnostic-market

Further key findings from the study suggest:

• On the basis of product, reagents held the largest share owing to increasing R&D activities in field of epigenetics. Kits are expected to witness high demand over the forecast period, expanding at a CAGR of 19.2% due to need for rapid and accurate detection techniques
• Based on technology, DNA methylation held a major share in terms of revenue in 2018. Technological advancements such as Methylation Sensitive PCR (MSP) and rapid adoption of these products to improve diagnostics efficiency are the factors attributing to its largest share
• Growing prevalence of cancer with epigenetic modification is a key factor driving the oncology application segment. Solid tumors further dominated the segment in 2018
• North America emerged as a major regional market in 2018 due to factors such as high levels of patient awareness, growing collaborations between large pharmaceutical firms for development of improved therapeutics, increasing funding for R&D, and increasing cancer prevalence
• The market in Asia Pacific is estimated to witness significant growth over the forecast period with a CAGR of 20.9% owing to the presence of large target population having cancer, diabetes, and other chronic disorders, along with parallel unmet clinical needs
• Major players of the industry include Sigma-Aldrich Corporation; Valirx Plc; Oncolys Biopharma Inc.; Zymo Research Corporation; Qiagen; Thermo Fisher Scientific; Diagenode Diagnostics; and Illumina, Inc. Extensive R&D initiatives for development of novel drugs and presence of strong product pipeline are expected to further boost the market growth over the forecast period.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
For More Information: www.grandviewresearch.com